Search This Blog

468x60.

728x90

 


37

The causes of SIADH are diverse and are shown in Table 27-1. Four different

patterns of inappropriate ADH release have been identified.

37 No correlation has

been found between these patterns and the underlying causes of SIADH, however.

Mechanisms for drug-induced SIADH include ADH-like action on the collecting

tubule, central stimulation of ADH release, and potentiation of the ADH effect.

37,57

Small-cell lung carcinoma is the most likely cause of C.C.’s SIADH.

CASE 27-7, QUESTION 2: Why was C.C.’s serum sodium concentration lower after the saline infusion?

Isotonic sodium chloride solution (154 mEq/L each of sodium and chloride ions,

or 308 mOsm/L) initially will increase the plasma sodium concentration because its

osmolality is higher than C.C.’s.

58 C.C., however, has a relatively fixed urine

osmolality of 616 mOsm/kg owing to persistent ADH activity; thus, he must excrete

an osmolar load of 616 mOsm in a volume of 1,000 mL of urine at steady state.

Because a total of 1 L of fluid containing 308 mOsm was administered, all the solutes

were excreted in 500 mL of urine output, and 500 mL of free water was retained to

cause a further dilution of sodium and a reduction in serum sodium concentration.

37,58

p. 577

p. 578

Neurologic Manifestations

CASE 27-7, QUESTION 3: Why are C.C.’s neurologic manifestations characteristic of hyponatremia?

As the plasma osmolality declines, the osmotic gradient created across the blood–

brain barrier favors the movement of water into the brain and other cells.

37,40 Water

movement from the cerebrospinal fluid into the cerebral interstitium results in

cerebral edema. Brain swelling is limited by the meninges and cranium, however,

giving rise to increased intracranial pressure and neurologic symptoms. The degree

of cerebral overhydration and the rapidity of its development appear to correlate

with the severity of symptoms.

37,40

When hyponatremia develops in less than 2 to 3 days or the rate of decline in

serum sodium is greater than 0.5 mEq/L/hour, the situation is regarded as acute.

37,59,60

The patient often becomes symptomatic when serum sodium concentration falls to

125 mEq/L; early complaints include nausea, vomiting, and malaise.

37,61 Severe

symptoms occur more commonly when the serum sodium falls to less than 120 mEq/L

and the rate of decline is greater than 0.5 mEq/L/hour. The patient may present with

headache, tremors, incoordination, delirium, lethargy, and obtundation. As the serum

sodium drops less than 110 to 115 mEq/L, seizure and coma may result.

37,61 On

occasion, severe brain edema leads to transtentorial herniation and eventually death.

Women, especially those who are premenopausal, apparently are more susceptible to

the development of severe neurologic symptoms and irreversible neurologic damage

than are men.

62,63

In contrast to acute hyponatremia, patients who are chronically hyponatremic are

usually asymptomatic.

37,59

If present, symptoms are usually vague and nonspecific and

tend to occur at lower serum sodium concentrations than those associated with

symptomatic acute hyponatremia.

37,59,61 The patient may experience anorexia, nausea,

vomiting, muscle weakness, and cramps. Irritability, hostility, confusion, and

personality changes may also be seen. At extremely low sodium levels, stupor and,

rarely, seizures have been reported.

Brain Adaptation to Hyponatremia

The difference in symptoms between acute and chronic hyponatremia is related to

cerebral adaptation to hypotonicity. Two adaptive mechanisms are important in

minimizing cerebral edema.

37,40,64,65 First, cerebral overhydration increases the

hydrostatic pressure in the cerebral interstitium, which results in the movement of

fluid from the cerebral interstitial space to the cerebrospinal fluid. Second, the

extrusion of intracellular solutes reduces cellular osmolality, which in turn enhances

water movement out of the cells. Sodium and potassium ions are the initial solutes

extruded, followed over a period of hours to days by osmolytes such as inositol,

glutamine, glutamate, and taurine.

64 Therefore, when the serum sodium concentration

falls faster than the onset of brain osmotic adaptation processes, serious and

permanent neurologic damage can occur.

37,40,64,65 On the other hand, when

hyponatremia develops over the course of 2 to 3 days, symptoms are not usually seen

unless the serum sodium concentration is reduced markedly.

It is often difficult to determine the acuity and chronicity of hyponatremia. Unless

an obvious cause for acute hyponatremia is found, assume that the condition is

chronic.

37,59,60,65 A rapid decline in serum sodium concentration usually suggests that

hypotonic fluid was administered to a patient with a condition that overwhelms or

impairs renal water excretion. These conditions include psychogenic polydipsia

35,36

;

postoperative hyponatremia

62,63,66,67

; postprostatectomy syndrome

39

; and

administration of thiazide diuretics,

41,42 parenteral cyclophosphamide,

68 oxytocin,

69

and arginine vasopressin or its analogs.

57 C.C.’s symptoms appear to have developed

over the course of 7 days and are consistent with chronic hyponatremia.

Rate of Correction of Hyponatremia

CASE 27-7, QUESTION 4: How should C.C.’s hyponatremia be managed?

C.C.’s water excess should be calculated to estimate the amount of water that

should be removed to achieve the desired sodium concentration.

where

The treatment of hyponatremia has been controversial. Severe hyponatremia is

associated with high rates of morbidity and mortality, but its treatment can also result

in morbidity. The rate of correction has been implicated as the main cause of

complications.

59–61,65,70–72

It takes time for the brain to lose osmolytes to reduce cerebral swelling during

hyponatremia; conversely, the rate of reaccumulation of these osmolytes must keep

pace with the rise in serum sodium concentration to avoid brain dehydration and

damage. Indeed, rapid correction of hyponatremia can cause a constellation of

neurologic findings known as osmotic demyelination syndrome (ODS).

71,72 Clinical

manifestations usually are delayed and occur one to several days after the treatment

has been started. Neurologic findings include transient behavioral changes, seizures,

akinetic mutism in mild cases, and features of a pontine disorder in severe cases

(pseudobulbar palsy, quadriparesis, and coma). In some patients, the damage is

irreversible, and central pontine myelinolysis can be documented in fatal cases.

Patients at greatest risk for osmotic demyelination are those with severe

hyponatremia lasting greater than 2 days and those in whom the rate of correction of

hyponatremia is greater than 12 mEq/L in any 24-hour period.

65,71,72 Hypokalemia,

which was found in about 90% of patients with ODS associated with rapid

hyponatremia correction, has been suspected as a predisposing factor in the

development of ODS.

72 Because the etiology of this complication is unclear, it may

be beneficial to correct the hypokalemia before correcting the severe hyponatremia.

72

Retrospective reviews suggest that acute hyponatremia can be treated safely at a

rate of 1 mEq/L/hour initially, until the serum sodium concentration reaches 120

mEq/L. Thereafter, the rate of correction should be reduced to less than or equal to

0.5 mEq/L/hour, such that an increment in sodium concentration does not exceed 12

mEq/L in the first 24 hours.

59,73 Slow correction is indicated for severe chronic

hyponatremia. No neurologic complications were seen in patients with severe

hyponatremia when the average rate of correction to serum sodium was less than 0.55

mEq/L/hour or when the increase in serum sodium was less than 12 mEq/L in 24

hours or less than 18 mEq/L in 48 hours.

73

In C.C., the serum sodium concentration should be raised to approximately 120

mEq/L at a correction rate of approximately 0.5 mEq/L/hour, using hypertonic saline

and furosemide. Serum sodium concentrations should be monitored closely because

the equation for calculating water excess does not take into account insensible loss,

which can increase the rate of sodium correction.

p. 578

p. 579

The use of normal saline is not useful in C.C. because he excretes salt normally

(urine sodium, 60 mEq/L). C.C.’s sodium deficit is as follows:

Because 1 L of 3% sodium chloride solution contains 513 mEq of sodium,

approximately 700 mL of 3% saline solution, which contains 360 mEq of sodium,

will be required to correct the sodium deficit. The recommended serum sodium

concentration correction rate is 0.5 mEq/L/hour; therefore, a minimum of 20 hours

will be needed to raise the serum sodium concentration by 10 mEq/L (from 110 to

120 mEq/L). The amount of sodium replacement to safely increase the serum sodium

concentration can be determined by the product of the rate of replacement (0.5

mEq/L/hour) and TBW (36 L, Eq. 27-10)—that is, 18 mEq/hour. The maximal rate of

infusion of 3% saline, which contains 0.513 mEq/mL of sodium, is therefore 35

mL/hour (18 mEq/hour)/(0.513 mEq/mL). A rate of 30 mL/hour, therefore, is

appropriate to safely replace C.C.’s sodium deficit.

Because calculations for water excess and sodium deficits are only

approximations, the patient’s serum osmolality, serum sodium, and clinical response

must be monitored closely. Urinary losses can be replaced with 3% sodium chloride

solution and appropriate amounts of potassium.

Chronic Management of the Syndrome of Inappropriate

Antidiuretic Hormone Secretion

CASE 27-7, QUESTION 5: How should C.C.’s SIADH be managed chronically?

SIADH is usually transient if the underlying cause can be removed. Chronic

SIADH can occur, however, as illustrated by C.C. Water restriction sufficient to

create a negative water balance is the primary therapy and should be attempted

first.

37,40

In general, all fluids, not just water, should be included in the restriction.

Salt intake, however, should not be reduced or solute depletion can occur. The extent

of fluid restriction depends on urine output, the amount of insensible water loss, and

urine osmolality. For a given amount of solute excretion, patients with a high urine

osmolality require a smaller volume of urine (i.e., more water retained) than those

with a lower urine osmolality (i.e., less water retained). Hence, more stringent water

restriction is required in patients with a high urine osmolality. Commonly, several

days of restriction are needed before a significant increase in plasma osmolality is

observed.

When fluid restriction fails to reverse the hypo-osmolar state or when the patient is

unwilling or unable to comply with the severe fluid restriction, drugs that antagonize

the effect of ADH can be used.

37,40 These include loop diuretics,

74,75

demeclocycline,

76 and lithium.

77 Furosemide (20–40 mg/day) reduces urine

osmolality by blocking the concentrating ability of the kidney.

74 Demeclocycline and

lithium directly impair the response to ADH at the collecting tubule, inducing

nephrogenic diabetes insipidus.

76,77 Demeclocycline (300–600 mg twice daily) is

usually better tolerated than lithium. Its effect on water excretion is delayed for a few

days, and it dissipates over a similar period of time after the drug is stopped.

Nephrotoxicity has been reported with its use in patients with cirrhosis.

78 Limited

data suggest that phenytoin may inhibit ADH secretion, but its effectiveness is

questionable.

79 Urea can correct hypo-osmolality by increasing solute-free water

excretion and reducing urinary sodium excretion.

80

It has been used effectively, at 30

to 60 g/day, both short term and long term, to reduce the need for fluid restriction.

81

An IV formulation of urea is available commercially; however, for oral

administration, 30 g of urea crystals can be dissolved in 10 mL of aluminum–

magnesium antacid and 100 mL of water. Orange juice or other strongly flavored

liquids can be used to improve palatability.

VASOPRESSIN RECEPTOR ANTAGONISTS

Nonpeptide vasopressin receptor antagonists (VRAs), also known as the “vaptans”

or “aquaretic agents,” constitute a class of agents used for the treatment of

hyponatremia. Arginine vasopressin (AVP), a neuropeptide hormone, plays an

important role in maintaining serum osmolality, as well as circulatory and sodium

homeostasis.

82,83 AVP exerts its physiologic effects by acting on V1A, V1B, and V2

receptors, causing effects such as vasoconstriction,

84,85 corticotropin release,

86 and

water excretion,

No comments:

Post a Comment

اكتب تعليق حول الموضوع

mcq general

 

Search This Blog